ACE2 and invasive breast carcinoma: In invasive breast carcinoma of no special type, elevated ACE2 immunostaining was linked to high grade, HER2 overexpression and loss of oestrogen and progesterone receptors (p < 0.0001 each) but was unrelated to patient outcome in the largest subgroup of invasive breast carcinomas of no special type (p = 0.6491; Figure 4B).